|
SUMO2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.07419694939904E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.68919989107508E-10 |
| Normal-vs-Stage2 |
2.782400E-02 |
| Normal-vs-Stage3 |
1.73471999999064E-05 |
| Normal-vs-Stage4 |
2.577900E-04 |
| Stage1-vs-Stage2 |
1.531010E-01 |
| Stage1-vs-Stage3 |
5.128400E-01 |
| Stage1-vs-Stage4 |
3.552200E-01 |
| Stage2-vs-Stage3 |
3.874400E-01 |
| Stage2-vs-Stage4 |
5.462000E-01 |
| Stage3-vs-Stage4 |
7.850000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.31349955754001E-10 |
| Normal-vs-AfricanAmerican |
1.015930E-04 |
| Normal-vs-Asian |
9.67269999999631E-05 |
| Caucasian-vs-AfricanAmerican |
9.465700E-02 |
| Caucasian-vs-Asian |
5.548000E-01 |
| AfricanAmerican-vs-Asian |
3.199000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.31799999978111E-07 |
| Normal-vs-Female |
7.2479000579051E-10 |
| Male-vs-Female |
5.694200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.90270046782371E-10 |
| Normal-vs-Age(41-60Yrs) |
2.94919999976884E-07 |
| Normal-vs-Age(61-80Yrs) |
1.655810E-03 |
| Normal-vs-Age(81-100Yrs) |
6.827500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.162100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.908200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.575000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.671800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.024000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.844200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.551200E-01 |
| Classical-VS-Follicular |
2.994100E-02 |
| Classical-VS-Other |
9.524400E-01 |
| Classical-VS-Normal |
2.87558865608162E-12 |
| Tall-VS-Follicular |
3.894600E-01 |
| Tall-VS-Other |
8.385400E-01 |
| Tall-VS-Normal |
6.137000E-03 |
| Follicular-VS-Other |
5.226200E-01 |
| Follicular-VS-Normal |
2.635600E-02 |
| Other-VS-Normal |
5.069500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.81189999998366E-06 |
| Normal-vs-N1 |
1.2835999999572E-06 |
| N0-vs-N1 |
3.077000E-01 |
|
|
